Five Prime Therapeutics Stock Price, News & Analysis (NASDAQ:FPRX)

$18.34 -0.41 (-2.19 %)
(As of 02/18/2018 03:25 AM ET)
Previous Close$18.34
Today's Range$18.30 - $19.11
52-Week Range$17.05 - $49.30
Volume324,107 shs
Average Volume553,080 shs
Market Capitalization$610.12 million
P/E Ratio-3.62
Dividend YieldN/A
Beta3.56

About Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Receive FPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:FPRX
CUSIPN/A
Phone+1-415-3655600

Debt

Debt-to-Equity RatioN/A
Current Ratio7.29%
Quick Ratio7.29%

Price-To-Earnings

Trailing P/E Ratio-3.61735700197239
Forward P/E Ratio-3.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.69 million
Price / Sales20.32
Cash FlowN/A
Price / CashN/A
Book Value$13.69 per share
Price / Book1.34

Profitability

Trailing EPS($5.07)
Net Income$-65,690,000.00
Net Margins-408.42%
Return on Equity-41.57%
Return on Assets-35.39%

Miscellaneous

Employees195
Outstanding Shares34,010,000

Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics Inc (NASDAQ:FPRX) posted its earnings results on Monday, November, 6th. The biotechnology company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($1.35) by $0.19. The biotechnology company earned $8.33 million during the quarter, compared to analysts' expectations of $16.16 million. Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The business's quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company earned ($0.72) EPS. View Five Prime Therapeutics' Earnings History.

Where is Five Prime Therapeutics' stock going? Where will Five Prime Therapeutics' stock price be in 2018?

6 equities research analysts have issued twelve-month price targets for Five Prime Therapeutics' stock. Their forecasts range from $50.00 to $94.00. On average, they expect Five Prime Therapeutics' stock price to reach $67.75 in the next year. View Analyst Ratings for Five Prime Therapeutics.

What are Wall Street analysts saying about Five Prime Therapeutics stock?

Here are some recent quotes from research analysts about Five Prime Therapeutics stock:

  • 1. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (2/14/2018)
  • 2. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)
  • 3. Cowen Inc analysts commented, "We believe Five Prime has amongst the leading IO drug discovery platforms in the industry. The BMS partnership provides validation. Multiple clinical readouts in 2017 provide catalysts to drive value generation. Lead asset Cabira has significant potential in solid tumors, we expect FPA144 to succeed in FGFR2b+ gastric cancer (2019), and we see high POS for Cabira in PVNS. Initiating at Outperform." (3/24/2017)
  • 4. Instinet analysts commented, "We are initiating on Five Prime Therapeutics (FPRX) with a Buy rating and a $94, 12-month target price. We recommend owning FPRX shares ahead of potentially transformational mid-2017 readouts. We anticipate 2017 data from cabiralizumab and key competitors will further de-risk cabiralizumab's anti-CSF1R mechanism in immuno-oncology, define pivotal clinical paths, establish initial market opportunities, and differentiate its safety versus competitors." (3/1/2017)

Who are some of Five Prime Therapeutics' key competitors?

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the folowing people:

  • Lewis T. Williams M.D. Ph.D., Executive Chairman of the Board (Age 67)
  • Aron Marc Knickerbocker MBA, President, Chief Executive Officer, Chief Operating Officer, Director (Age 47)
  • Marc L. Belsky, Chief Financial Officer, Senior Vice President (Age 61)
  • Kevin Baker Ph.D., Senior Vice President, Development Sciences (Age 56)
  • Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer (Age 54)
  • Francis Willard Sarena J.D., Chief Strategy Officer and Secretary (Age 46)
  • Mark D. McDade, Lead Independent Director (Age 61)
  • Garry Nicholson, Director
  • Franklin M. Berger, Independent Director (Age 67)
  • Fred E. Cohen Ph.D. M.D., Independent Director (Age 60)

Who owns Five Prime Therapeutics stock?

Five Prime Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.46%), Victory Capital Management Inc. (2.72%), Rock Springs Capital Management LP (1.25%), Teachers Advisors LLC (0.80%), Millennium Management LLC (0.78%) and Amundi Pioneer Asset Management Inc. (0.60%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Franklin M Berger, Lewis T Williams, Marc Belsky, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

Who sold Five Prime Therapeutics stock? Who is selling Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Millennium Management LLC, Bank of New York Mellon Corp, BlackRock Inc., Cornerstone Capital Management Holdings LLC., Schwab Charles Investment Management Inc., UBS Asset Management Americas Inc. and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Five Prime Therapeutics.

Who bought Five Prime Therapeutics stock? Who is buying Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Rock Springs Capital Management LP, Amundi Pioneer Asset Management Inc., Two Sigma Investments LP, RTW Investments LP, Altrinsic Global Advisors LLC, Two Sigma Advisers LP and AWM Investment Company Inc.. View Insider Buying and Selling for Five Prime Therapeutics.

How do I buy Five Prime Therapeutics stock?

Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of Five Prime Therapeutics stock can currently be purchased for approximately $18.34.

How big of a company is Five Prime Therapeutics?

Five Prime Therapeutics has a market capitalization of $610.12 million and generates $30.69 million in revenue each year. The biotechnology company earns $-65,690,000.00 in net income (profit) each year or ($5.07) on an earnings per share basis. Five Prime Therapeutics employs 195 workers across the globe.

How can I contact Five Prime Therapeutics?

Five Prime Therapeutics' mailing address is 111 Oyster Point Blvd, SOUTH SAN FRANCISCO, CA 94080-1910, United States. The biotechnology company can be reached via phone at +1-415-3655600.


MarketBeat Community Rating for Five Prime Therapeutics (FPRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  319
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Five Prime Therapeutics (NASDAQ:FPRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $67.75$67.75$67.75$66.25
Price Target Upside: 54.82% upside54.82% upside54.82% upside132.37% upside

Five Prime Therapeutics (NASDAQ:FPRX) Consensus Price Target History

Price Target History for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics (NASDAQ:FPRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017BMO Capital MarketsBoost Price TargetOutperform$71.00 -> $75.00N/AView Rating Details
11/6/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$41.00 -> $50.00N/AView Rating Details
9/12/2017Jefferies GroupReiterated RatingBuy$52.00HighView Rating Details
3/24/2017CowenInitiated CoverageOutperformHighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$94.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
11/7/2016Credit Suisse GroupReiterated RatingBuy$54.00N/AView Rating Details
10/25/2016CitigroupInitiated CoverageBuy$65.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingOutperform$45.00 -> $58.00N/AView Rating Details
5/19/2016OppenheimerReiterated RatingOutperform$48.00N/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Five Prime Therapeutics (NASDAQ:FPRX) Earnings History and Estimates Chart

Earnings by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics (NASDAQ FPRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($1.35)($1.55)$16.16 million$8.33 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.15)($1.58)$8.32 million$7.80 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.96)($1.21)$6.05 million$10.13 millionViewListenView Earnings Details
2/23/2017Q4 2016($0.57)($0.73)$7.09 million$8.30 millionViewN/AView Earnings Details
11/3/2016Q3($0.51)($0.72)$7.50 million$6.70 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.49)$6.38 million$9.23 millionViewN/AView Earnings Details
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details
5/13/2015Q1($0.46)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details
3/17/2015Q414($0.40)($0.55)$5.39 million$4.65 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.40)($0.33)$5.22 million$6.06 millionViewN/AView Earnings Details
8/5/2014Q2 14($0.27)($0.46)$5.39 million$4.98 millionViewN/AView Earnings Details
5/8/2014Q1 2014($0.37)($0.46)ViewN/AView Earnings Details
3/25/2014Q4($0.40)($0.43)$1.52 million$3.79 millionViewListenView Earnings Details
11/12/2013($0.57)($2.74)$2.50 million$3.48 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Five Prime Therapeutics (NASDAQ:FPRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-5.56 EPS
Next Year EPS Consensus Estimate: $-5 EPS

Dividends

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Five Prime Therapeutics (NASDAQ FPRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.50%
Institutional Ownership Percentage: 72.14%
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics (NASDAQ FPRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2017William R RingoDirectorSell600$45.33$27,198.00600View SEC Filing  
10/2/2017William R RingoDirectorSell1,800$40.26$72,468.001,200View SEC Filing  
9/28/2017William R RingoDirectorSell2,000$38.00$76,000.002,000View SEC Filing  
3/1/2017William R RingoDirectorSell500$46.73$23,365.00500View SEC Filing  
2/1/2017William R RingoDirectorSell500$46.17$23,085.00500View SEC Filing  
1/18/2017Francis Willard SarenaInsiderSell3,636$47.39$172,310.0482,460View SEC Filing  
1/3/2017William R RingoDirectorSell500$51.07$25,535.00500View SEC Filing  
12/23/2016Lewis T WilliamsCEOSell30,000$50.50$1,515,000.00434,047View SEC Filing  
12/1/2016William R RingoDirectorSell500$57.72$28,860.00500View SEC Filing  
11/28/2016Francis Willard SarenaInsiderSell1,710$60.14$102,839.4082,976View SEC Filing  
11/25/2016Francis Willard SarenaInsiderSell34,654$60.38$2,092,408.5294,731View SEC Filing  
11/9/2016Peder JensenDirectorSell8,130$55.30$449,589.004,065View SEC Filing  
11/1/2016William R RingoDirectorSell500$48.67$24,335.00500View SEC Filing  
10/3/2016William R RingoDirectorSell500$52.00$26,000.00500View SEC Filing  
9/1/2016William R RingoDirectorSell500$44.20$22,100.00500View SEC Filing  
8/1/2016William R RingoDirectorSell500$50.77$25,385.00500View SEC Filing  
7/27/2016Peder JensenDirectorSell12,195$49.50$603,652.5012,195View SEC Filing  
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.0081,980View SEC Filing  
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.0088,410View SEC Filing  
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55341,078View SEC Filing  
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.4077,890View SEC Filing  
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00341,933View SEC Filing  
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00343,253View SEC Filing  
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09366,477View SEC Filing  
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.5681,278View SEC Filing  
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.0088,284View SEC Filing  
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18349,743View SEC Filing  
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.7685,751View SEC Filing  
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59363,611View SEC Filing  
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15340,352View SEC Filing  
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48294,593View SEC Filing  
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88366,945View SEC Filing  
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Five Prime Therapeutics (NASDAQ FPRX) News Headlines

Source:
DateHeadline
Five Prime Therapeutics (FPRX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowFive Prime Therapeutics (FPRX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 15 at 5:01 PM
Five Prime Therapeutics (FPRX) Downgraded to Sell at Zacks Investment ResearchFive Prime Therapeutics (FPRX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - February 14 at 11:42 PM
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27
finance.yahoo.com - February 14 at 9:35 AM
An Intrinsic Value Calculation For Five Prime Therapeutics Inc (NASDAQ:FPRX) Shows It’s 42.22% UndervaluedAn Intrinsic Value Calculation For Five Prime Therapeutics Inc (NASDAQ:FPRX) Shows It’s 42.22% Undervalued
finance.yahoo.com - February 14 at 9:35 AM
Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare ConferenceFive Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 9:37 AM
Five Prime Therapeutics (FPRX) Rating Lowered to Sell at Zacks Investment ResearchFive Prime Therapeutics (FPRX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 8 at 11:14 PM
Five Prime Therapeutics (FPRX) Downgraded by BidaskClubFive Prime Therapeutics (FPRX) Downgraded by BidaskClub
www.americanbankingnews.com - February 5 at 11:58 PM
Five Prime Therapeutics Inc (FPRX) Receives Consensus Recommendation of "Buy" from AnalystsFive Prime Therapeutics Inc (FPRX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 2 at 5:30 PM
Five Prime Therapeutics (FPRX) Stock Rating Upgraded by Zacks Investment ResearchFive Prime Therapeutics (FPRX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 31 at 11:58 PM
Five Prime Therapeutics Announces Closing of Upsized Public OfferingFive Prime Therapeutics Announces Closing of Upsized Public Offering
finance.yahoo.com - January 30 at 10:11 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Dermira, Denali Therapeutics, Epizyme, and Five Prime TherapeuticsQuotidian Technical Highlights on Selected Biotech Stocks -- Dermira, Denali Therapeutics, Epizyme, and Five Prime Therapeutics
www.prnewswire.com - January 29 at 6:52 AM
BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers SquibbBRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb
www.reuters.com - January 26 at 9:45 AM
Five Prime Therapeutics (FPRX) Downgraded by Zacks Investment ResearchFive Prime Therapeutics (FPRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 25 at 11:16 PM
BRIEF-Five Prime Announces Pricing Of Upsized Public Offering Of Common StockBRIEF-Five Prime Announces Pricing Of Upsized Public Offering Of Common Stock
www.reuters.com - January 25 at 9:37 AM
Five Prime Announces Pricing of Upsized Public Offering of Common StockFive Prime Announces Pricing of Upsized Public Offering of Common Stock
finance.yahoo.com - January 25 at 9:37 AM
Five Prime Announces Proposed Public Offering of Common StockFive Prime Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 24 at 10:12 AM
$9.86 Million in Sales Expected for Five Prime Therapeutics Inc (FPRX) This Quarter$9.86 Million in Sales Expected for Five Prime Therapeutics Inc (FPRX) This Quarter
www.americanbankingnews.com - January 19 at 1:00 PM
Zacks: Brokerages Anticipate Five Prime Therapeutics Inc (FPRX) to Announce -$1.29 Earnings Per ShareZacks: Brokerages Anticipate Five Prime Therapeutics Inc (FPRX) to Announce -$1.29 Earnings Per Share
www.americanbankingnews.com - January 17 at 8:20 AM
Five Prime Therapeutics (FPRX) Secures $5M IND Milestone Payment from Bristol-Myers Squibb (BMY) Under Immune ... - StreetInsider.comFive Prime Therapeutics (FPRX) Secures $5M IND Milestone Payment from Bristol-Myers Squibb (BMY) Under Immune ... - StreetInsider.com
www.streetinsider.com - January 9 at 5:15 PM
BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers SquibbBRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb
www.reuters.com - January 8 at 9:43 AM
Head-To-Head Comparison: Stemline Therapeutics (STML) versus Five Prime Therapeutics (FPRX)Head-To-Head Comparison: Stemline Therapeutics (STML) versus Five Prime Therapeutics (FPRX)
www.americanbankingnews.com - January 7 at 1:10 AM
Five Prime Therapeutics (FPRX) Submits Investigational NDA for Novel B7-H4 Antibody FPA150Five Prime Therapeutics (FPRX) Submits Investigational NDA for Novel B7-H4 Antibody FPA150
www.streetinsider.com - January 3 at 5:14 PM
Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare ConferenceFive Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 5:14 PM
Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150
finance.yahoo.com - January 3 at 5:14 PM
Pharma News Today (TRVN,FPRX,TTPH) - NasdaqPharma News Today (TRVN,FPRX,TTPH) - Nasdaq
www.nasdaq.com - January 3 at 8:50 AM
Five Prime Therapeutics (FPRX) Initiates Patient Dosing in Phase 1 ... - StreetInsider.comFive Prime Therapeutics (FPRX) Initiates Patient Dosing in Phase 1 ... - StreetInsider.com
www.streetinsider.com - January 3 at 8:50 AM
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric CancerFive Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer
finance.yahoo.com - January 2 at 6:31 PM
Five Prime Therapeutics Inc (FPRX) Expected to Announce Quarterly Sales of $9.86 MillionFive Prime Therapeutics Inc (FPRX) Expected to Announce Quarterly Sales of $9.86 Million
www.americanbankingnews.com - January 2 at 10:30 AM
Five Prime Therapeutics: Is This A High-Five Investment? - Seeking AlphaFive Prime Therapeutics: Is This A High-Five Investment? - Seeking Alpha
seekingalpha.com - January 1 at 9:36 AM
Zacks: Brokerages Anticipate Five Prime Therapeutics Inc (FPRX) Will Post Earnings of -$1.29 Per ShareZacks: Brokerages Anticipate Five Prime Therapeutics Inc (FPRX) Will Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - December 31 at 1:26 PM
ETFs with exposure to Five Prime Therapeutics, Inc. : December 26, 2017ETFs with exposure to Five Prime Therapeutics, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 9:02 AM
Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:58 PM
Five Prime Therapeutics (FPRX) Upgraded at BidaskClubFive Prime Therapeutics (FPRX) Upgraded at BidaskClub
www.americanbankingnews.com - December 22 at 12:10 AM
BRIEF-Five Prime Therapeutics And Zai Lab Announce Exclusive License AgreementBRIEF-Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement
www.reuters.com - December 20 at 5:10 PM
Five Prime Therapeutics (FPRX), Zai Lab Announce Pact for FPA144 Anti-FGFR2b Antibody in Greater China and ... - StreetInsider.comFive Prime Therapeutics (FPRX), Zai Lab Announce Pact for FPA144 Anti-FGFR2b Antibody in Greater China and ... - StreetInsider.com
www.streetinsider.com - December 19 at 5:10 PM
Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development CollaborationFive Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Collaboration
finance.yahoo.com - December 19 at 5:10 PM
Five Prime Therapeutics Inc (FPRX) Given Consensus Recommendation of "Hold" by AnalystsFive Prime Therapeutics Inc (FPRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 14 at 9:26 PM
Five Prime Therapeutics Inc (FPRX) Expected to Post Earnings of -$1.29 Per ShareFive Prime Therapeutics Inc (FPRX) Expected to Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - December 14 at 5:08 PM
ETFs with exposure to Five Prime Therapeutics, Inc. : December 13, 2017ETFs with exposure to Five Prime Therapeutics, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 5:22 PM
BidaskClub Downgrades Five Prime Therapeutics (FPRX) to SellBidaskClub Downgrades Five Prime Therapeutics (FPRX) to Sell
www.americanbankingnews.com - December 9 at 9:50 AM
Five Prime Therapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare ConferenceFive Prime Therapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 4 at 5:11 PM
Five Prime Therapeutics, Inc. (FPRX) Short Interest UpdateFive Prime Therapeutics, Inc. (FPRX) Short Interest Update
www.americanbankingnews.com - November 29 at 2:08 AM
Zacks: Analysts Anticipate Five Prime Therapeutics, Inc. (FPRX) Will Post Quarterly Sales of $9.86 MillionZacks: Analysts Anticipate Five Prime Therapeutics, Inc. (FPRX) Will Post Quarterly Sales of $9.86 Million
www.americanbankingnews.com - November 28 at 9:50 AM
Zacks: Brokerages Expect Five Prime Therapeutics, Inc. (FPRX) Will Post Earnings of -$1.29 Per ShareZacks: Brokerages Expect Five Prime Therapeutics, Inc. (FPRX) Will Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - November 26 at 1:28 PM
Five Prime Therapeutics, Inc. (FPRX) Given Average Recommendation of "Hold" by BrokeragesFive Prime Therapeutics, Inc. (FPRX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 19 at 5:32 PM
Why This Biotech Still Gets Hit Despite Promising Cancer DataWhy This Biotech Still Gets Hit Despite Promising Cancer Data
finance.yahoo.com - November 13 at 5:52 PM
Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune ...Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune ...
www.nasdaq.com - November 10 at 5:25 PM
Five Prime Therapeutics (FPRX) Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at SITCFive Prime Therapeutics (FPRX) Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at SITC
www.streetinsider.com - November 10 at 5:25 PM
Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual MeetingFive Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting
finance.yahoo.com - November 10 at 5:25 PM
Five Prime Therapeutics, Inc. (FPRX) Expected to Announce Quarterly Sales of $9.86 MillionFive Prime Therapeutics, Inc. (FPRX) Expected to Announce Quarterly Sales of $9.86 Million
www.americanbankingnews.com - November 9 at 10:31 AM

SEC Filings

Five Prime Therapeutics (NASDAQ:FPRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Five Prime Therapeutics (NASDAQ:FPRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Five Prime Therapeutics (NASDAQ FPRX) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.